Business context and reporting period
The supplied filing is Rexahn Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2013—not a filing by Opus Genetics, Inc. The company described itself as a development-stage biopharmaceutical business focused on cancer and other drug candidates; it had no commercial sales revenue.
Financial results and liquidity
| Metric | Three months ended June 30, 2013 | Six months ended June 30, 2013 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $1.91 million | $3.82 million |
| Net loss | $3.11 million | $4.64 million |
| Basic and diluted loss per share | $0.03 | $0.04 |
| Cash used in operating activities | — | $4.06 million |
At June 30, cash and cash equivalents were $9.98 million, marketable securities $0.10 million, and restricted cash equivalents $0.57 million; together these totaled $10.65 million. Current assets were $10.47 million and current liabilities $5.57 million. Total liabilities were $5.57 million, including $3.66 million of warrant liabilities; the filing reports no conventional debt balance. Accumulated deficit was $67.95 million.
Material changes versus prior comparable periods
- Second-quarter net loss increased from $1.04 million in 2012 to $3.11 million in 2013. The main unusual driver was a $1.21 million non-cash loss from revaluing warrant liabilities, compared with a $0.80 million gain in the prior-year quarter.
- Six-month net loss rose from $3.18 million to $4.64 million. The warrant revaluation changed from a $0.54 million gain in 2012 to a $0.84 million loss in 2013.
- Six-month general and administrative expense increased 40.7% to $2.07 million, primarily reflecting CEO recruiting and stock-option compensation, as well as investor-relations services.
- Six-month research and development expense declined 28.3% to $1.48 million, largely because Teva-funded RX-3117 development costs reduced a deferred research-funding liability rather than being recorded as expense.
- Cash declined by $3.51 million from year-end 2012. Cash used in operations increased to $4.06 million from $3.90 million in the first half of 2012.
Outlook, management commentary, and risks
Management stated that cash, restricted cash, marketable securities, and proceeds from a subsequent offering were expected to fund cash-flow needs into 2015; it also estimated that June 30 resources alone would cover minimum planned operating needs for 18–24 months. These expectations depend on spending priorities and development plans. Management said additional financing would be needed to execute the broader operating plan, with no assurance it could be obtained on acceptable terms.
- Planned focus included Phase II work on Archexin, Phase I trials for RX-3117 and RX-5902, and preclinical pipeline development. The filing estimated minimum next-12-month spending of approximately $2.1 million for Archexin trials, $1.3 million for RX-3117 and RX-5902, $2.7 million for preclinical and other R&D, $3.0 million for general corporate expenses, and $150,000 for facilities rent.
- RX-3117: Teva submitted an IND application in July 2013; the company anticipated a Phase I trial in the second half of 2013. RX-5902 might enter Phase I in the third quarter of 2013. These were plans, not assurances.
- Archexin’s completed Phase IIa pancreatic-cancer study reported median survival of 9.1 months among evaluable patients, compared with historical 5.65-month survival for single-agent gemcitabine; this was an open-label study and the comparator was historical.
- Serdaxin and Zoraxel were not receiving development resources; Rexahn was seeking partners. The company said development, clinical-trial, regulatory, financing, and intellectual-property uncertainties could delay or prevent progress.
- Subsequent events: July warrant exercises generated $1.20 million in cash. On July 26, the company completed a registered direct offering of 11.4 million shares and warrants for gross proceeds of $5.70 million, before offering costs; the warrants could add dilution and were classified as liabilities.
- Other notable obligations included approximately $20.89 million in estimated total R&D vendor-contract costs, much of which had already been paid, and a lease extension through June 2019 with approximately $910,000 in scheduled future rent. The filing reported no legal proceedings and no material changes to previously disclosed risk factors.
Most important facts for investors to verify
- Confirm the issuer: this source is Rexahn Pharmaceuticals, Inc., not Opus Genetics, Inc.
- Review the cash runway assumptions, planned trial spending, and the terms and net proceeds of the July 2013 offering.
- Assess the clinical evidence and current regulatory status of Archexin, RX-3117, and RX-5902, including whether anticipated trial milestones occurred.
- Check warrant-liability valuation and potential dilution: warrant remeasurement materially affected reported losses, and 21.6 million warrants were outstanding at June 30, 2013.
- Reconcile the filing’s stated future financing needs with its runway estimates and the development costs required to advance the pipeline.